Cryosite (CTE.AX) Saham Harga
Cryosite Harga
Selama 19 tahun terakhir pendapatan Cryosite tumbuh 6,9% per tahun, mencapai 16,70 Juta. AUD. Laba per saham tumbuh 4,1% per tahun selama 19 tahun terakhir. Bagi Cryosite, margin bersih sebesar 13,4% naik dibanding 11,6% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 1,64%. Rasio pembayaran sekitar 91% dari laba. Dividen tumbuh 5,5% per tahun selama 13 tahun terakhir.
Harga saham Cryosite
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Cryosite
Pertanyaan yang sering diajukan tentang saham Cryosite
The business model of Cryosite Ltd focuses on providing biobanking and cell therapy services. Cryosite specializes in the collection, storage, and distribution of human biological samples such as cord blood, tissue, and cells for medical and research purposes. The company allows individuals and families to preserve cord blood stem cells for potential future use in regenerative medicine. Cryosite also offers cell therapy manufacturing services to support personalized medicine and clinical trials. With its expertise and advanced technology, Cryosite aims to contribute to advancements in medical treatments and research, offering peace of mind to those seeking to preserve their biological materials.
Cryosite Ltd is primarily active in the biomedical and life sciences industries.
The main competitors of Cryosite Ltd in the market are companies like Stemlife, Singapore Cord Blood Bank, and CordLife Group Limited.
Cryosite Ltd, a reputable Australian company, has an intriguing history and background. Established in 2000, Cryosite has played a pivotal role in the field of biomedical services. The company specializes in secure storage and transportation of precious biological samples, supporting medical research, clinical trials, and stem cell transplant programs. With state-of-the-art facilities and stringent quality control measures, Cryosite has gained recognition as a trusted partner for numerous healthcare institutions and research organizations globally. Over the years, Cryosite Ltd has showcased its expertise in preserving and managing these life-changing resources, contributing significantly to advancements in healthcare and cutting-edge research.
Cryosite Ltd has achieved several significant milestones. Firstly, the company successfully established itself as a leading provider of comprehensive storage solutions for stem cells, reproductive tissues, and cord blood in Australia. Additionally, Cryosite Ltd expanded its services by offering advanced cryopreservation techniques, ensuring the long-term viability of stored materials. The company's commitment to quality led to accreditation by the Therapeutic Goods Administration (TGA) and attainment of ISO 9001 certification. Furthermore, Cryosite Ltd expanded its client base, attracting partnerships with major healthcare institutions and research organizations. These milestones demonstrate Cryosite Ltd's success in delivering trusted and state-of-the-art cryogenic storage services to its clients.
Cryosite Ltd primarily operates in Australia and New Zealand.
Cryosite Ltd is a leading company that values integrity, reliability, and innovation. With a strong corporate philosophy focused on providing premium services and solutions in the field of biobanking and reproductive services, Cryosite is committed to excellence. The company strives to ensure the utmost trust and transparency in all its operations, delivering high-quality cryopreservation services, cord blood banking, and stem cell research facilities. Cryosite Ltd continuously pushes boundaries through cutting-edge technology and strategic partnerships, aiming to meet the evolving needs of its customers and make a positive impact in the healthcare industry.
Dengan kurs saat ini, saham Cryosite diperdagangkan pada 0,76 EUR (1,22 AUD).
Saham Cryosite (CTE.AX) tercatat di 1 bursa, termasuk: ASX (CTE.AX).
Cryosite Ltd is an Australian company that has been operating in the field of biological material storage for over 15 years. With a wide range of services and products, the company has established itself as a leading provider of cryo-storage solutions in Australia.
Pendapatan dari Cryosite adalah 16,70 Juta. AUD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba dari Cryosite adalah 2,24 Juta. AUD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Cryosite saat ini adalah 28,49. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Cryosite.
Rasio harga-terhadap-penjualan (PSR) Cryosite saat ini adalah 3,81. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Cryosite.
Skor Kualitas AlleAktien untuk Cryosite adalah 7/10.
ISIN dari Cryosite adalah AU000000CTE1. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Cryosite adalah 621943. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Cryosite adalah CTE.AX. Simbol ticker digunakan untuk memperdagangkan saham Cryosite di bursa saham.
Saham Cryosite
Kelompok Peer Cryosite
Cryosite Ticker
Cryosite FIGI
Semua metrik fundamental dan analisis mendalam Cryosite
Analisis saham kami untuk saham Cryosite mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Cryosite. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.